Benzinga | Oct 6, 2021 06:25AM EDT

HC Wainwright & Co. Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $160

HC Wainwright & Co. analyst Douglas Tsao maintains Biohaven Pharma Hldgs (NYSE:BHVN) with a Buy and raises the price target from $135 to $160.